Literature DB >> 9376975

The efficacy of interferon alpha on colchicine-resistant familial Mediterranean fever attacks: a pilot study.

M Tunca1, E Tankurt, H Akbaylar Akpinar, S Akar, N Hizli, O Gönen.   

Abstract

About a quarter of familial Mediterranean fever (FMF) patients have recurrent painful attacks of polyserositis despite regular colchicine treatment. There is no known alternative drug for colchicine-resistant cases. We had previously observed a patient with FMF whose painful attacks disappeared during the 6 month period of interferon alpha (IFN) treatment for his chronic hepatitis B. The objective of the present study was to investigate the possible beneficial effect of IFN on these episodes. Twenty-one consecutive attacks in seven adult patients with FMF were treated at early onset with IFN, the dosage being 3-10 million I U s.c. Eighteen of the 21 attacks could be halted in a mean time of 3.05 h, while the intensity of abdominal pain remained very low. Observed side-effects were generally mild and acceptable. IFN may be a useful adjunct for the treatment of colchicine-resistant attacks in FMF patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9376975     DOI: 10.1093/rheumatology/36.9.1005

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  10 in total

1.  Familial Mediterranean Fever and Multiple Sclerosis Successfully Treated With Interferon Beta-1a: A Case Report.

Authors:  Bilgin Öztürk
Journal:  Arch Rheumatol       Date:  2019-04-22       Impact factor: 1.472

Review 2.  Familial Mediterranean fever.

Authors:  Fatos Onen
Journal:  Rheumatol Int       Date:  2005-11-10       Impact factor: 2.631

Review 3.  Familial Mediterranean fever.

Authors:  Aysin Bakkaloglu
Journal:  Pediatr Nephrol       Date:  2003-06-27       Impact factor: 3.714

Review 4.  Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy.

Authors:  Jae J Chae; Ivona Aksentijevich; Daniel L Kastner
Journal:  Br J Haematol       Date:  2009-05-14       Impact factor: 6.998

5.  E148Q/M694I mutation in 3 Japanese patients with familial Mediterranean fever.

Authors:  Yasuko Kotone-Miyahara; Akifumi Takaori-Kondo; Keiko Fukunaga; Masashi Goto; Yasuaki Hayashino; Makoto Miki; Hiroshi Takayama; Masataka Sasada; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2004-04       Impact factor: 2.490

Review 6.  Hereditary auto-inflammatory disorders and biologics.

Authors:  Leigh D Church; Sarah M Churchman; Philip N Hawkins; Michael F McDermott
Journal:  Springer Semin Immunopathol       Date:  2006-05-04

7.  Abdominal pain, arthritis, and nephrotic syndrome in a Syrian patient.

Authors:  Bruno Eduardo P Balbo; André Albuquerque Silva; Andressa Godoy Amaral; Denise M A C Malheiros; Luiz Fernando Onuchic; Rui Toledo Barros
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

8.  Dapsone as an alternative therapy in children with familial mediterranean Fever.

Authors:  Farhad Salehzadeh; Sepideh Jahangiri; Elnaz Mohammadi
Journal:  Iran J Pediatr       Date:  2012-03       Impact factor: 0.364

9.  Renal and suprarenal insufficiency secondary to familial Mediterranean fever associated with amyloidosis: a case report.

Authors:  Ahmet Burak Toros; Fusun Erdenen; Nagehan Didem Sari; Serkan Gokcay
Journal:  J Med Case Rep       Date:  2011-08-18

10.  Long-term familial Mediterranean fever remission on successful hepatitis C virus treatment in a patient not responding to colchicine: a case report.

Authors:  Manik Gemilyan; Gagik Hakobyan; Susanna Ananyan
Journal:  J Med Case Rep       Date:  2018-05-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.